AFFINI-T THERAPEUTICS, INC. logo

AFFINI-T THERAPEUTICS, INC.

12 Marks
Corp.
First Filed:Aug 21, 2020Latest Filed:Jun 6, 2025Address:100 Forge Road, Watertown, MA 02472, US

Portfolio Overview

Top Classes

Class 42
Software, IT Services & Scientific Research
8(67%)
Class 5
Pharmaceuticals
6(50%)
Class 44
Medical, beauty and agricultural services
1(8%)

TTAB Proceedings

Total Proceedings
1
As Plaintiff
0(0%)
As Defendant
1(100%)

Top Firms

Loading...

Trademark Portfolio

12 results

(current & previous marks)

Refine by Mark/Description🔽
Filed
Registered
Last Activity
TAILOR
TAILOR
Service Mark
Word
ABANDONED
Owner:
Serial:99222386
Filed:Jun 6, 2025
Classes:42
Description: Scientific study and research in the field(s) of cancer therapy, namely through the identification of T-cells targeting oncogenic driver peptides
REDIRECT BIOLOGICS
REDIRECT BIOLOGICS
Trademark
Word
PENDING
Owner:
Serial:98620870
Filed:Jun 26, 2024
Classes:5, 42
Description: Biological preparations for the treatment of cancer; Chemical reagents for medical purposes; Medical and scientific research in the field of analysis and treatment of multiple tumor-associated antigens utilizing T-Cell Engagers
REDIRECT THERAPEUTICS
REDIRECT THERAPEUTICS
Trademark
Word
ABANDONED
Owner:
Serial:98620903
Filed:Jun 26, 2024
Classes:5, 42
Description: Biological preparations for the treatment of cancer; Chemical reagents for medical purposes; "THERAPEUTICS"; Medical and scientific research in the field of analysis and treatment of multiple tumor-associated antigens utilizing T-Cell Engagers
THRIVE
THRIVE
Service Mark
Word
REGISTERED
Owner:
Serial:98579402
Filed:May 31, 2024
Classes:42
Registration:7814609
Registered:Jun 3, 2025
Description: Research and development in the field of genetically modified cells, namely research and development of manufacturing processes for the production of fit and proliferative T-cells exhibiting naive and stem cell memory phenotypes through gene editing and cell therapy manufacturing for the treatment of patients having solid tumors by eradicating metastatic cells
TETHER
TETHER
Trademark
Word
PENDING
Owner:
Serial:98347552
Filed:Jan 8, 2024
Classes:5, 42
Description: Biological preparations for the treatment of cancer identifying highly specific and potent T-cell receptors used against endogenously presented oncogenic driver peptides; Chemical reagents for medical purposes; Medical and scientific research in the field of analysis and treatment of cancer utilizing T-cells
T
T
Trademark
Combined
REGISTERED
Owner:
Serial:97786800
Filed:Feb 8, 2023
Classes:5
Registration:7868544
Registered:Jul 15, 2025
Description: Biological preparations for the treatment of cancer; Chemical reagents for medical purposes
TAILOR
TAILOR
Service Mark
Word
PENDING
Owner:
Serial:97786843
Filed:Feb 8, 2023
Classes:42
Description: Research in the field of cell engineering technology
THRIVE
THRIVE
Service Mark
Word
ABANDONED
Owner:
Serial:97786836
Filed:Feb 8, 2023
Classes:44
TUNE
TUNE
Service Mark
Word
ABANDONED
Owner:
Serial:97786852
Filed:Feb 8, 2023
Classes:42
Description: Research in the field of cell engineering technology
AFFINI T
AFFINI T
Trademark
Combined
REGISTERED
Owner:
Serial:97322946
Filed:Mar 21, 2022
Classes:5
Registration:7210297
Registered:Nov 7, 2023
Description: Biological preparations for the treatment of cancer; Chemical reagents for medical purposes | Medical and scientific research in the field of analysis and treatment of multiple tumor-associated antigens utilizing T-cells
AFFINI-T
AFFINI-T
Trademark
Word
REGISTERED
Owner:
Serial:97322827
Filed:Mar 21, 2022
Classes:5
Registration:7764869
Registered:Apr 22, 2025
Description: Biological preparations for the treatment of cancer; Chemical reagents for medical purposes ,all of the foregoing in the field of analysis and treatment of multiple tumor associated antigens utilizing immune cells
AFFINI-T
AFFINI-T
Service Mark
Word
REGISTERED
Owner:
Serial:90130538
Filed:Aug 21, 2020
Classes:42
Registration:6570559
Registered:Nov 23, 2021
Description: Medical and scientific research in the field of analysis and treatment of multiple tumor-associated antigens utilizing T-cells